![Western Blot: RUNX1T1/ETO Antibody [NBP3-18685] - Figure 2A: Construction of GST-fusion proteins containing different parts of RUNX1T1/ETO constructed and run on 15% polyacrylamide gel. Figure 2B: Western blot performed on seven GST-fusion proteins containing different fragments of RUNX1T1/ETO (1-7) with antibody against RUNX1T1/ETO , 1:1000 in TBS-Tween, 5% skimmed milk. MW marker (in kDa) is shown on the left; location of the protein of interest indicated on the right. Antibody raised against RUNX1T1/ETO recognizes ETO part (lane 2) of fusion protein. Figure 2C: Western blot performed on nuclear extracts from KAS-6/1 cells (human myeloma cell line) and SKNO-1 cells (human acute myeloblastic leukaemia) with antibody against RUNX1T1/ETO , diluted 1:1,000 in TBS-Tween containing 5% skimmed milk. Left, a MW marker is shown (in kDa). The location of RUNX1T1/ETO and a presumed splice variant (missing 106 C-terminal amino acids) are indicated on the right.](http://images.novusbio.com/fullsize/RUNX1T1-ETO-Antibody-Western-Blot-NBP3-18685-img0002.jpg "Western Blot: RUNX1T1/ETO Antibody [NBP3-18685] - Figure 2A: Construction of GST-fusion proteins containing different parts of RUNX1T1/ETO constructed and run on 15% polyacrylamide gel. Figure 2B: Western blot performed on seven GST-fusion proteins containing different fragments of RUNX1T1/ETO (1-7) with antibody against RUNX1T1/ETO , 1:1000 in TBS-Tween, 5% skimmed milk. MW marker (in kDa) is shown on the left; location of the protein of interest indicated on the right. Antibody raised against RUNX1T1/ETO recognizes ETO part (lane 2) of fusion protein. Figure 2C: Western blot performed on nuclear extracts from KAS-6/1 cells (human myeloma cell line) and SKNO-1 cells (human acute myeloblastic leukaemia) with antibody against RUNX1T1/ETO , diluted 1:1,000 in TBS-Tween containing 5% skimmed milk. Left, a MW marker is shown (in kDa). The location of RUNX1T1/ETO and a presumed splice variant (missing 106 C-terminal amino acids) are indicated on the right.")
| Reactivity | HuSpecies Glossary |
| Applications | WB, ELISA |
| Clonality | Polyclonal |
| Host | Rabbit |
| Conjugate | Unconjugated |
| Concentration | 0.2 mg/ml |
| Immunogen | Polyclonal antibody raised in rabbit against the RUNX1T1/ETO (RUNX1) fusion protein, using 3 different KLH-conjugated synthetic peptides. The antibody recognizes the ETO (RUNX1T1) part of the fusion protein. |
| Clonality | Polyclonal |
| Host | Rabbit |
| Gene | RUNX1T1 |
| Purity | Affinity purified |
| Innovator's Reward | Test in a species/application not listed above to receive a full credit towards a future purchase. |
| Storage | Store at -20C short term. Aliquot and store at -80C long term. Avoid freeze-thaw cycles. |
| Buffer | PBS |
| Preservative | 0.05% Sodium Azide and 0.05% ProClin 300 |
| Concentration | 0.2 mg/ml |
| Purity | Affinity purified |
Secondary Antibodies |
Isotype Controls |
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
![ELISA: RUNX1T1/ETO Antibody [NBP3-18685] - Figure 1. Determination of the antibody titer To determine the titer of the antibody, an ELISA was performed using a serial dilution of the antibody directed against RUNX1T1/ETO , crude serum and flow through in antigen coated wells. By plotting the absorbance against the antibody dilution (Figure 1), the titer of the antibody was estimated to be 1:5,250.](http://images.novusbio.com/fullsize/RUNX1T1-ETO Antibody-ELISA-NBP3-18685-img0001.jpg "ELISA: RUNX1T1/ETO Antibody [NBP3-18685] - Figure 1. Determination of the antibody titer To determine the titer of the antibody, an ELISA was performed using a serial dilution of the antibody directed against RUNX1T1/ETO , crude serum and flow through in antigen coated wells. By plotting the absorbance against the antibody dilution (Figure 1), the titer of the antibody was estimated to be 1:5,250.")
![Western Blot c-Abl Antibody [Unconjugated]](https://images.novusbio.com/images2/c-Abl_AF5414_Western_Blot_5714.jpg)
![Simple Western c-Abl Antibody [Unconjugated]](https://images.novusbio.com/images2/cAbl_AF5414_Simple_Western_17046.jpg)
![Immunohistochemistry CD34 Antibody [Unconjugated]](https://images.novusbio.com/images2/CD34_AF4117_Immunohistochemistry_6824.jpg)
![Bioactivity GM-CSF [Unconjugated]](https://images.novusbio.com/images/protein/7954-gmcf_recombinant-human-gm-csf-cho-expressed-protein-cf-bioactivity-272020121514.jpg)
![Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).](https://images.novusbio.com/images/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-HRP-Western-Blot-NB7160-img0001.jpg "Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).")